Report Detail
Global Intraveno(IV) Iron Drugs Market Insights, Forecast to 2025
- RnM3398209 |
- 08 May, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
Major drivers of the IV iron drugs market are increase in incidence of iron deficiency, rise in chronic kidney disease patients undergoing dialysis, and surging diabetic population. Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance of oral therapy, and accurate, easy, and convenient access to IV iron dosages drive demand for intravenous iron drugs. However, complex approval process, stringent regulations, drug side effects, nutraceutical alternatives to prevent iron deficiency, and product price are likely to act as major restraints of the IV iron drugs market.
The global Intraveno(IV) Iron Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Intraveno(IV) Iron Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Intraveno(IV) Iron Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Intraveno(IV) Iron Drugs in these regions.
This research report categorizes the global Intraveno(IV) Iron Drugs market by top players/brands, region, type and end user. This report also studies the global Intraveno(IV) Iron Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Allergan
AMAG Pharmaceuticals
Galenica
Actavis
American Regent
Sanofi
Luitpold Pharmaceuticals
Fresenius Medical Care
Pharmacosmos
Vifor Pharma
Market size by Product
Low Molecular Weight Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxyl Maltose
Market size by End User
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Intraveno(IV) Iron Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Intraveno(IV) Iron Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Intraveno(IV) Iron Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Intraveno(IV) Iron Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Intraveno(IV) Iron Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Intraveno(IV) Iron Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Intraveno(IV) Iron Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Intraveno(IV) Iron Drugs Market Size Growth Rate by Product
- 1.4.2 Low Molecular Weight Iron Dextran
- 1.4.3 Ferric Gluconate
- 1.4.4 Iron Sucrose
- 1.4.5 Ferric Carboxyl Maltose
- 1.5 Market by End User
- 1.5.1 Global Intraveno(IV) Iron Drugs Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Ambulatory Surgical Centers
- 1.5.4 Diagnostic Centers
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Intraveno(IV) Iron Drugs Market Size
- 2.1.1 Global Intraveno(IV) Iron Drugs Revenue 2014-2025
- 2.1.2 Global Intraveno(IV) Iron Drugs Sales 2014-2025
- 2.2 Intraveno(IV) Iron Drugs Growth Rate by Regions
- 2.2.1 Global Intraveno(IV) Iron Drugs Sales by Regions
- 2.2.2 Global Intraveno(IV) Iron Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Intraveno(IV) Iron Drugs Sales by Manufacturers
- 3.1.1 Intraveno(IV) Iron Drugs Sales by Manufacturers
- 3.1.2 Intraveno(IV) Iron Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Intraveno(IV) Iron Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Intraveno(IV) Iron Drugs Revenue by Manufacturers
- 3.2.1 Intraveno(IV) Iron Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Intraveno(IV) Iron Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Intraveno(IV) Iron Drugs Price by Manufacturers
- 3.4 Intraveno(IV) Iron Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Intraveno(IV) Iron Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Intraveno(IV) Iron Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Intraveno(IV) Iron Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Intraveno(IV) Iron Drugs Sales by Product
- 4.2 Global Intraveno(IV) Iron Drugs Revenue by Product
- 4.3 Intraveno(IV) Iron Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Intraveno(IV) Iron Drugs Breakdown Data by End User
6 North America
- 6.1 North America Intraveno(IV) Iron Drugs by Countries
- 6.1.1 North America Intraveno(IV) Iron Drugs Sales by Countries
- 6.1.2 North America Intraveno(IV) Iron Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Intraveno(IV) Iron Drugs by Product
- 6.3 North America Intraveno(IV) Iron Drugs by End User
7 Europe
- 7.1 Europe Intraveno(IV) Iron Drugs by Countries
- 7.1.1 Europe Intraveno(IV) Iron Drugs Sales by Countries
- 7.1.2 Europe Intraveno(IV) Iron Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Intraveno(IV) Iron Drugs by Product
- 7.3 Europe Intraveno(IV) Iron Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Intraveno(IV) Iron Drugs by Countries
- 8.1.1 Asia Pacific Intraveno(IV) Iron Drugs Sales by Countries
- 8.1.2 Asia Pacific Intraveno(IV) Iron Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Intraveno(IV) Iron Drugs by Product
- 8.3 Asia Pacific Intraveno(IV) Iron Drugs by End User
9 Central & South America
- 9.1 Central & South America Intraveno(IV) Iron Drugs by Countries
- 9.1.1 Central & South America Intraveno(IV) Iron Drugs Sales by Countries
- 9.1.2 Central & South America Intraveno(IV) Iron Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Intraveno(IV) Iron Drugs by Product
- 9.3 Central & South America Intraveno(IV) Iron Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Intraveno(IV) Iron Drugs by Countries
- 10.1.1 Middle East and Africa Intraveno(IV) Iron Drugs Sales by Countries
- 10.1.2 Middle East and Africa Intraveno(IV) Iron Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Intraveno(IV) Iron Drugs by Product
- 10.3 Middle East and Africa Intraveno(IV) Iron Drugs by End User
11 Company Profiles
- 11.1 Allergan
- 11.1.1 Allergan Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Allergan Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Allergan Intraveno(IV) Iron Drugs Products Offered
- 11.1.5 Allergan Recent Development
- 11.2 AMAG Pharmaceuticals
- 11.2.1 AMAG Pharmaceuticals Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AMAG Pharmaceuticals Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AMAG Pharmaceuticals Intraveno(IV) Iron Drugs Products Offered
- 11.2.5 AMAG Pharmaceuticals Recent Development
- 11.3 Galenica
- 11.3.1 Galenica Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Galenica Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Galenica Intraveno(IV) Iron Drugs Products Offered
- 11.3.5 Galenica Recent Development
- 11.4 Actavis
- 11.4.1 Actavis Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Actavis Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Actavis Intraveno(IV) Iron Drugs Products Offered
- 11.4.5 Actavis Recent Development
- 11.5 American Regent
- 11.5.1 American Regent Company Details
- 11.5.2 Company Business Overview
- 11.5.3 American Regent Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 American Regent Intraveno(IV) Iron Drugs Products Offered
- 11.5.5 American Regent Recent Development
- 11.6 Sanofi
- 11.6.1 Sanofi Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Sanofi Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Sanofi Intraveno(IV) Iron Drugs Products Offered
- 11.6.5 Sanofi Recent Development
- 11.7 Luitpold Pharmaceuticals
- 11.7.1 Luitpold Pharmaceuticals Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Luitpold Pharmaceuticals Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Luitpold Pharmaceuticals Intraveno(IV) Iron Drugs Products Offered
- 11.7.5 Luitpold Pharmaceuticals Recent Development
- 11.8 Fresenius Medical Care
- 11.8.1 Fresenius Medical Care Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Fresenius Medical Care Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Fresenius Medical Care Intraveno(IV) Iron Drugs Products Offered
- 11.8.5 Fresenius Medical Care Recent Development
- 11.9 Pharmacosmos
- 11.9.1 Pharmacosmos Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Pharmacosmos Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Pharmacosmos Intraveno(IV) Iron Drugs Products Offered
- 11.9.5 Pharmacosmos Recent Development
- 11.10 Vifor Pharma
- 11.10.1 Vifor Pharma Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Vifor Pharma Intraveno(IV) Iron Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Vifor Pharma Intraveno(IV) Iron Drugs Products Offered
- 11.10.5 Vifor Pharma Recent Development
12 Future Forecast
- 12.1 Intraveno(IV) Iron Drugs Market Forecast by Regions
- 12.1.1 Global Intraveno(IV) Iron Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Intraveno(IV) Iron Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Intraveno(IV) Iron Drugs Market Forecast by Product
- 12.2.1 Global Intraveno(IV) Iron Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Intraveno(IV) Iron Drugs Revenue Forecast by Product 2019-2025
- 12.3 Intraveno(IV) Iron Drugs Market Forecast by End User
- 12.4 North America Intraveno(IV) Iron Drugs Forecast
- 12.5 Europe Intraveno(IV) Iron Drugs Forecast
- 12.6 Asia Pacific Intraveno(IV) Iron Drugs Forecast
- 12.7 Central & South America Intraveno(IV) Iron Drugs Forecast
- 12.8 Middle East and Africa Intraveno(IV) Iron Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Intraveno(IV) Iron Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Intraveno(IV) Iron Drugs . Industry analysis & Market Report on Intraveno(IV) Iron Drugs is a syndicated market report, published as Global Intraveno(IV) Iron Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Intraveno(IV) Iron Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
